Does Fosamax Cause Osteonecrosis of the Jaw?

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Education to Targeted Risk Inquiry

The legacy context of general health and science information has long served as a foundation for public understanding of medical conditions and treatment options. Within this broad framework, discussions of medication side effects and patient safety have been central, particularly as they relate to chronic disease management. This heritage emphasizes the importance of informed decision-making and awareness of potential risks associated with therapeutic interventions. Transitioning from this general health perspective, a more focused examination emerges regarding specific pharmaceutical exposures and their potential consequences. In the domain of mass production and widespread drug distribution, the question of causation between a commonly prescribed medication and a serious adverse event becomes paramount. The target query regarding Fosamax and osteonecrosis of the jaw exemplifies this shift from broad health education to a precise occupational exposure concern. Here, the concern is not merely about general health literacy but about the implications of sustained, population-level exposure to a drug in clinical practice. This pivot requires a neutral, evidence-informed approach that acknowledges the legacy of health communication while zeroing in on the specific risk profile associated with long-term bisphosphonate use, without venturing into mechanistic claims or citing external evidence. The focus remains on the transition from general awareness to a targeted inquiry into exposure and outcome.

Understanding Fosamax and Its Mechanism

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The drug works by inhibiting bone resorption, thereby increasing bone mass and reducing fracture risk. However, a known adverse effect associated with bisphosphonate use, including Fosamax, is osteonecrosis of the jaw (ONJ). Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region, often occurring spontaneously but more commonly associated with dental procedures such as tooth extraction or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The clinical presentation typically involves pain, swelling, and exposed bone in the jaw, which can lead to significant morbidity. Diagnosis is based on clinical examination and imaging, with a focus on ruling out other causes such as malignancy or infection.

Evidence Linking Fosamax to Osteonecrosis of the Jaw

The mechanistic pathways linking Fosamax to ONJ are not fully elucidated, but current understanding suggests that bisphosphonates, including alendronate, suppress bone turnover by inhibiting osteoclast activity. This suppression can impair the normal remodeling and repair processes in the jawbone, particularly after dental trauma or infection. A multiscale characterization of jawbone has provided comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). The jawbone's high vascularity and constant mechanical stress may make it uniquely susceptible to this complication. The time to onset of ONJ symptoms after starting Fosamax can vary widely, from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In clinical studies, the incidence of ONJ was low, and in placebo-controlled trials of Fosamax, the percentages of patients with symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a subset of patients experienced recurrence of symptoms when rechallenged with the same drug or another bisphosphonate, suggesting a causal relationship in susceptible individuals.

Risk Factors and Clinical Management

Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, or ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with longer duration of bisphosphonate exposure. For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific section on osteonecrosis of the jaw under "Warnings and Precautions" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This section advises discontinuation of the drug if severe symptoms develop and notes that most patients had relief of symptoms after stopping. The label also highlights that ONJ has been reported in patients taking bisphosphonates, including Fosamax, and lists known risk factors. However, the label does not provide specific guidance on the optimal duration of use for fracture prevention, noting that the optimal duration has not been determined and that for low-risk patients, discontinuation after 3 to 5 years may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Causation Considerations and Conclusion

For affected patients, causation considerations involve evaluating the temporal relationship between Fosamax exposure and the development of ONJ, as well as the presence of other risk factors. The timeline between exposure and documented harm can range from days to months, and recurrence upon rechallenge supports a causal link. Patients who develop ONJ while on Fosamax should be managed in consultation with a dental professional, and discontinuation of the bisphosphonate may be considered, especially if invasive dental procedures are planned. In summary, while Fosamax is effective for osteoporosis and other bone conditions, it carries a known risk of osteonecrosis of the jaw, particularly in patients with additional risk factors. The prescribing information provides warnings, but the risk-benefit balance must be individualized, especially for long-term use.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the connection between Fosamax and osteonecrosis of the jaw?

Fosamax (alendronate) is a bisphosphonate that can cause osteonecrosis of the jaw (ONJ) as a known adverse effect. The drug suppresses bone turnover, which may impair jawbone healing after dental procedures or infection, leading to exposed, non-healing bone. The prescribing information includes warnings about this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

How long does it take for Fosamax to cause jaw problems?

The time to onset of ONJ symptoms after starting Fosamax can vary widely, from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Some patients may develop symptoms quickly, while others may take longer, especially if additional risk factors are present.

What are the risk factors for developing osteonecrosis of the jaw while on Fosamax?

Risk factors include invasive dental procedures (tooth extraction, implants), cancer diagnosis, chemotherapy, corticosteroids, poor oral hygiene, periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Longer duration of bisphosphonate use also increases risk.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Check Whether Your Situation Qualifies

Free and confidential. No obligation — an initial records screening only.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.